{
  "id": 10205051,
  "title": "Oscar Health director Vanessa Wittman sells $806,000 in stock",
  "url": "https://urgent.news/2026/09/27/oscar-health-director-vanessa-wittman-sells-806-000-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-27T11:16:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/oscar-health-director-vanessa-wittman-sells-806000-in-stock-93CH-4918950"
  },
  "original_language": "en",
  "account": "Oscar Health's director, Vanessa Wittman, sold 25,000 shares of the company's Class A Common Stock on September 18, 2026, for a total of $806,000. She executed this sale under a Rule 10b5-1 trading plan, adopted on June 18, 2026. The sale price of $32.24 per share was higher than the current stock price of $29.60, which had decreased by 7.9% over the previous week. Despite this recent decline, the stock has shown strong performance over the past year, increasing by 61% and by 166% over the last six months. According to InvestingPro analysis, Oscar Health appears to be fairly valued at its current stock price, with an additional 11 ProTips available to subscribers. After this transaction, Wittman personally holds 112,121 shares of Oscar Health Class A Common Stock, which includes shares expected to be issued upon the vesting of restricted stock units. Recently, Oscar Health reported stronger-than-expected second-quarter 2026 results, with adjusted earnings of $1.10 per share and revenue of $4.88 billion, surpassing analysts' estimates. The company's improved performance was credited to record first-half profitability, better medical-cost management, and more efficient expense control. Oscar Health also updated its 2026 guidance, raising its operating income forecast to between $600 million and $800 million. Investment firms like Piper Sandler and BofA Securities have maintained varying perspectives on the company's future, with Piper Sandler raising its price target to $48 and maintaining an Overweight rating, while BofA Securities increased its target to $30 but kept an Underperform rating. These updates paint a picture of Oscar Health's current financial standing and future prospects for investors.",
  "summary": null,
  "key_points": [
    "Vanessa Wittman sold 25,000 shares of Oscar Health stock for $806,000.",
    "Sale executed under Rule 10b5-1 plan, price per share was $32.24.",
    "Despite recent 7.9% drop, stock up 61% over past year."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}